Teva Pharmaceutical to redeem €650 million of 3/8% notes

By Sarah Lizee

Olympia, Wash., Nov. 21 – Teva Pharmaceutical Industries Ltd. said Teva Pharmaceutical Finance Netherlands II BV plans to redeem €650 million of its outstanding 3/8% senior notes due 2020, according to a notice.

The notes will be redeemed on Dec. 9 at a redemption price equal to the greater of par and the sum of the present values of the remaining scheduled payments on the redeemed notes, discounted on an annual basis at the reinvestment rate, in either case, accrued interest.

After giving effect to the redemption, the total amount of notes outstanding will be €1,010,154,000.

Teva is a pharmaceutical company based in Petah Tikva, Israel.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.